Anastrazole 1mg/tab 30 Tabletten by Magnus Pharmaceuticals

Usage

1. Establish your washout window first: confirm that synthetic androgens have cleared to sub-pharmacological levels before initiating anastrozole — the induction phase has no mechanistic rationale while exogenous androgens continue to aromatize at cycle-level rates.
2. Begin the induction phase at 1 mg per day (one full tablet), taken orally with or without food. Anastrozole absorption is not meaningfully affected by fed or fasted state.
3. Schedule a serum estradiol blood draw at the end of week two. Use this result — not a fixed calendar date — as the trigger for transitioning to the maintenance dose.
4. If estradiol is within the normal reference range, reduce to 0.5 mg every other day by splitting the 1 mg tablet. Use a clean pill cutter for accurate halving; do not estimate by eye.
5. At week four or five, begin the taper: extend the dosing interval to every third day for one week, then to every fourth day for the final week before stopping. This stepped reduction allows aromatase activity to recover gradually.
6. Run a final hormone panel (LH, FSH, total testosterone, estradiol) after discontinuation to confirm HPG axis recovery. If values remain suppressed, extend monitoring rather than restarting anastrozole — consult a qualified medical professional for clinical guidance.

Warnings

Frequently asked questions

How should anastrozole dosing be structured across a full PCT protocol?

A structured anastrozole PCT protocol runs in three phases: an induction phase at up to 1 mg per day, a maintenance phase at 0.5 mg every other day once estradiol is controlled, and a taper phase stepping the dose down before discontinuation. Phase transitions should be guided by mid-protocol serum estradiol values rather than fixed calendar dates to avoid over- or under-suppression.

Should anastrozole dose be tapered down gradually at the end of PCT?

Yes — abrupt anastrozole discontinuation can trigger a rapid estradiol rebound as aromatase enzyme activity resumes without constraint. A seven- to fourteen-day taper, reducing the dose stepwise from the maintenance level to every-third-day dosing before stopping, allows the body's estrogen regulation to normalise progressively rather than spiking post-PCT.

What factors determine how long an anastrozole PCT protocol should run?

Protocol length is driven by serum hormone recovery markers — LH, FSH, and total testosterone must return to normal reference ranges before anastrozole is discontinued. Calendar-based endpoints are a secondary guide only; bloodwork at weeks four and six of PCT provides the objective endpoint criteria that the protocol length should be built around.

Can Magnus Pharmaceuticals Anastrozole 1mg tablets be split for lower doses?

Yes. Magnus Pharmaceuticals Anastrozole tablets are manufactured to GMP content uniformity standards, with HPLC verification confirming even API distribution across the tablet matrix. This means a tablet can be reliably split to deliver an approximately 0.5 mg half-dose, which is the standard maintenance and taper dose in most PCT protocols.

How many tablets are needed for a complete variable-dose PCT protocol?

A standard induction-maintenance-taper protocol typically consumes between 20 and 30 tablets over five to six weeks, depending on the induction dose frequency and the length of the taper. Magnus Pharmaceuticals' 30-tablet pack is sized to cover a complete protocol in a single purchase, eliminating mid-cycle resupply risk that can disrupt dosing continuity. (2) angle_used

Manufacturer

Formulation development at Magnus Pharmaceuticals is approached as a compound-specific engineering task rather than a one-size-fits-all tablet production process — and Anastrozole 1mg/tab illustrates this philosophy through its precision dosing design. At the 1 mg API load per tablet, the technical challenge is not compression force but distribution uniformity: achieving a consistent active concentration across every tablet in a 30-unit batch demands validated granulation parameters and rigorous in-process sampling at compression. Magnus Pharmaceuticals addresses this through a structured analytical protocol in which content uniformity data is generated at the finished-tablet stage — separate from, and not substituted by, incoming API purity data — before any batch is cleared for release. The resulting certificate of analysis covers HPLC-determined anastrozole content, dissolution behaviour, and tablet physical parameters, and is issued per production lot. This batch-specific documentation architecture means that dose integrity claims for Anastrozole 1mg/tab are backed by measurement data specific to that lot, not extrapolated from API certificates or historical averages.